Vandana Abramson is an Oncology physician. OpenAlex indexes 444 publications with 12,028 citations (h-index 50); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372320021
Telephone
615-936-2000Provider last certified this registry record 23 Mar 2022.
Clinical trials
- Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Sponsor: Vandana Abramson
- Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Sponsor: Vanderbilt-Ingram Cancer Center
- Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Sponsor: Vanderbilt-Ingram Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202523 payments$44,172openpaymentsdata.cms.gov ↗
- Samsung Bioepis Co., Ltd.Program year20255 payments
- Genentech USA, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor62.3%Ibrance80%Kisqali20%Part D<11 patientsAromatase Inhibitor30.1%Letrozole68%Anastrozole32%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Improving Outcomes for Patients with Triple-Negative Breast Cancer
Vanderbilt University Medical Center
FY2026$400,313R01CA312128 - Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
Vanderbilt University Medical Center
FY2018$461,172U01CA142565 - Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
Vanderbilt University Medical Center
FY2017$461,999U01CA142565
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
Journal of the National Comprehensive Cancer Network
2025 - Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
Journal of the National Comprehensive Cancer Network
2023
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”